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Introduction: Alteration of γ-aminobutyric acid “A” (GABAA) receptor-mediated neurotransmission has been
associated with various neurological and psychiatric disorders. [11C]Ro15-4513 is a PET ligand with high
aﬃnity for α5-subunit-containing GABAA receptors, which are highly expressed in limbic regions of the human
brain (Sur et al., 1998). We quantiﬁed the test-retest reproducibility of measures of [11C]Ro15-4513 binding
derived from six diﬀerent quantiﬁcation methods (12 variants).
Methods: Five healthy males (median age 40 years, range 38–49 years) had a 90-min PET scan on two
occasions (median interval 12 days, range 11–30 days), after injection of a median dose of 441 MegaBequerels
of [11C]Ro15-4513. Metabolite-corrected arterial plasma input functions (parent plasma input functions, ppIFs)
were generated for all scans.
We quantiﬁed regional binding using six methods (12 variants), some of which were region-based (applied to
the average time-activity curve within a region) and others were voxel-based: 1) Models requiring arterial ppIFs
– regional reversible compartmental models with one and two tissue compartments (2kbv and 4kbv); 2)
Regional and voxelwise Logan’s graphical analyses (Logan et al., 1990), which required arterial ppIFs; 3) Model-
free regional and voxelwise (exponential) spectral analyses (SA; (Cunningham and Jones, 1993)), which also
required arterial ppIFs; 4) methods not requiring arterial ppIFs – voxelwise standardised uptake values
(Kenney et al., 1941), and regional and voxelwise simpliﬁed reference tissue models (SRTM/SRTM2) using
brainstem or alternatively cerebellum as pseudo-reference regions (Lammertsma and Hume, 1996; Gunn et al.,
1997).
To compare the variants, we sampled the mean values of the outcome parameters within six bilateral, non-
reference grey matter regions-of-interest. Reliability was quantiﬁed in terms of median absolute percentage test-
retest diﬀerences (MA-TDs; preferentially low) and between-subject coeﬃcient of variation (BS-CV, preferen-
tially high), both compounded by the intraclass correlation coeﬃcient (ICC). These measures were compared
between variants, with particular interest in the hippocampus.
Results: Two of the six methods (5/12 variants) yielded reproducible data (i.e. MA-TD < 10%): regional SRTMs
and voxelwise SRTM2s, both using either the brainstem or the cerebellum; and voxelwise SA. However, the
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SRTMs using the brainstem yielded a lower median BS-CV (7% for regional, 7% voxelwise) than the other
variants (8–11%), resulting in lower ICCs. The median ICCs across six regions were 0.89 (interquartile range
0.75–0.90) for voxelwise SA, 0.71 (0.64–0.84) for regional SRTM-cerebellum and 0.83 (0.70–0.86) for
voxelwise SRTM-cerebellum. The ICCs for the hippocampus were 0.89 for voxelwise SA, 0.95 for regional
SRTM-cerebellum and 0.93 for voxelwise SRTM-cerebellum.
Conclusion: Quantiﬁcation of [11C]Ro15-4513 binding shows very good to excellent reproducibility with SRTM
and with voxelwise SA which, however, requires an arterial ppIF. Quantiﬁcation in the α5 subunit-rich
hippocampus is particularly reliable. The very low expression of the α5 in the cerebellum (Fritschy and Mohler,
1995; Veronese et al., 2016) and the substantial α1 subunit density in this region may hamper the application of
reference tissue methods.
1. Introduction
γ-aminobutyric acid (GABA) is one of the principal inhibitory
neurotransmitters in the brain (Curtis et al., 1970). The ligand-gated,
ion channel GABAA receptor (Lobo and Harris, 2008) is a pentameric
structure assembled from ﬁve of 19 known protein subunits: α1–6, β1–3,
γ1–3, δ, ε, π, ρ1–3 and θ (Barnard et al., 1998). On binding GABA, the
permeability of the central pore to chloride ions increases, resulting in
hyperpolarisation of the neuron and hence reduced excitability. The
receptor subunits exhibit distinct but overlapping distributions within
the brain (Fritschy and Mohler, 1995; Sieghart and Sperk, 2002) and
roles that change during development and with pathologies
(Galanopoulou, 2008).
Approximately 5% of GABAA receptors contain the α5 subunit. The
hippocampus is the structure with the highest concentration of α5-
subunit-containing receptors in the human brain; for example, an ex
vivo study with the α5-subunit-selective radioligand [3H]L-655,708
suggested they are present in almost 28% of GABAA receptors in this
region (Sur et al., 1998). Here, they have a predominantly extra-
synaptic localisation (Brunig et al., 2002) and mediate tonic inhibitory
currents (Caraiscos et al., 2004). Experiments in animals suggest that
agonists at receptors containing the α5 subunit negatively inﬂuence
hippocampus-dependent learning and memory (Collinson et al., 2002;
Crestani et al., 2002; Sternfeld et al., 2004; Yee et al., 2004; Cheng
et al., 2006; Dawson et al., 2006). Whilst data in humans is lacking, the
amnestic eﬀect of alcohol on wordlist learning was reduced by pre-
treatment with an α5-subunit-selective inverse agonist (Nutt et al.,
2007).
Alteration of GABAA receptor-mediated neurotransmission has
been associated with a wide variety of neurological and psychiatric
disorders (Korpi and Sinkkonen, 2006), including alcohol dependence,
anxiety (reviewed by Roy-Byrne (2005)), epilepsy ((Macdonald et al.,
2004), reviewed by Gonzalez and Brooks-Kayal (2011)), and schizo-
phrenia (reviewed by Charych et al. (2009)).
The synthesis of subtype-selective tracers such as Ro15-4513
(ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodia-
zepine-3-carboxylate; F. Hoﬀmann–La Roche Ltd., Basel, Switzerland)
promises further understanding of GABAA receptors. Ro15-4513 is an
α5-subunit-selective imidazodiazepine that behaves as a partial inverse
agonist at GABAA receptors (Bonetti et al., 1988; Lister and Nutt, 1988;
Sadzot et al., 1989). Receptors that express α5 subunits have 10–15-
fold higher aﬃnity to Ro15-4513 than those that do not (Hadingham
et al., 1993; Luddens et al., 1994). Competition studies in the rat in
vivo revealed that radiolabelled Ro15-4513 binding was reduced to
nonspeciﬁc levels only by drugs that have aﬃnity for the α5 subtype
(ﬂunitrazepam, RY80, Ro15-4513, L655,708) and that [11C]Ro15-
4513 has a tenfold higher aﬃnity to α5 than α1 receptors (Lingford-
Hughes et al., 2002).
In healthy human volunteers, pre-scan administration of the α1
antagonist zolpidem did not signiﬁcantly decrease total [11C]Ro15-
4513 volume-of-distribution (VT; (Myers et al., 2012)), but alteration of
the fast (α1) component peaks (derived using exponential spectral
analysis; SA) was observed. In the α5-rich hippocampus, the mean
volume-of-distribution attributable to the fast peaks was reduced by
approximately 70% to 0.44, whereas a slower component (presumably
attributable to the a5 subunit) was reduced by approximately 13% to
10.00. More recently, human heterologous competition data acquired
from nine healthy males using the α5-subunit-selective negative
allosteric modulator, Basmisanil (RG1662), suggested that α5-speciﬁc
binding accounts for 76% of the speciﬁc binding in the hippocampus
(Myers et al., 2016).
Inoue et al. (1992) used the simpliﬁed reference tissue model
(SRTM) with pons as a (pseudo-) reference region to demonstrate the
diﬀerences between the distribution of [11C]Ro15-4513 and [11C]
ﬂumazenil in ﬁve healthy participants. [11C]Ro15-4513 VT has also
been previously quantiﬁed by voxel-wise exponential SA in three
healthy males (Lingford-Hughes et al., 2002). Comparison with [11C]
ﬂumazenil PET derived from six healthy males indicated signiﬁcantly
greater VT (by approximately 36%) in the hippocampus for [
11C]Ro15-
4513, with signiﬁcantly less binding (approximately 43%) in the
cerebellum.
[11C]Ro15-4513 binding has also been quantiﬁed in eight healthy
men using both compartmental modelling and linear graphical ana-
lyses (Asai et al., 2009); the SRTM with pons as a reference was
recommended based on resilience to noise, but test – retest studies
were not performed.
[11C]Ro15-4513 PET has recently been used to demonstrate
alterations in GABAA α5 subunit binding in alcohol dependence
(Lingford-Hughes et al., 2012), schizophrenia (Asai et al., 2008), in
response to levodopa challenge (Lou et al., 2016), and in preliminary
studies in temporal lobe epilepsy (Barros et al., 2010a) and autism
spectrum disorder (Mendez et al., 2013). To facilitate interpretation, it
is necessary to document the reproducibility and reliability of quanti-
tative methods, both regional and voxelwise, for [11C]Ro15-4513 PET.
Whilst the test – retest variability of presumed α1- and α5-subunit-
speciﬁc VT has been reported (Stokes et al., 2014), the variability of
total VT has not. Moreover, the analysis performed by Stokes and
colleagues was restricted to a single quantiﬁcation method (SA),
whereas variants that do not require an arterial input function, and
variants which yield parametric images, still merit investigation.
However, no such analysis has been published.
In the present study we quantiﬁed the test-retest reproducibility
and reliability of measures of [11C]Ro15-4513 binding derived from six
quantiﬁcation methods, namely standardised uptake values (SUVs),
one tissue compartment and two tissue compartment models (2kbv
and 4kbv), graphical (linear) analyses, SA, and SRTMs, in regions
representative of a variety of α5 subunit concentrations, in ﬁve healthy
volunteers.
2. Materials and methods
2.1. Participants
The study was approved by the London – Riverside National Health
Service (NHS) Research Ethics Committee, Imperial College
Healthcare NHS Trust, and University College London Hospitals
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NHS Foundation Trust. Permission to administer [11C]Ro15-4513 was
obtained from the Administration of Radioactive Substances Advisory
Committee, UK. All participants provided written, informed consent
according to the Declaration of Helsinki prior to participation in the
study.
Seven healthy male participants were recruited and provided
written, informed consent. The exclusion criteria were: a history of
either neurological or psychiatric condition(s), claustrophobia, any
contraindication for undergoing magnetic resonance (MR) imaging, a
positive urine drug test, general practitioner’s (family doctor’s) advice
against participation, regular medication(s) (especially benzodiaze-
pines), a history of substance abuse (especially benzodiazepines), and
a pathological modiﬁed Allen’s test for patency of the ulnar artery
(Allen, 1929; Slogoﬀ et al., 1983; Cable et al., 1999). Two of the seven
participants were subsequently excluded: one who withdrew from the
study before the second scan, and another in whom the arterial line
could not be kept patent for the entire study. Hence, a total of ﬁve
healthy male participants (median age 40 years, range 38–49 years;
Table 1) were scanned twice. All participants underwent a urine drug
cassette test for 11-nor-Δ9-tetrahydrocannabinol, morphine, ampheta-
mine, benzoylecgonine (the main metabolite of cocaine), methamphe-
tamine and oxazepam (Monitect; BMC, California, USA) on the same
day as each PET scan.
2.2. Radiochemistry
[11C]Ro15-4513 was produced on site by Hammersmith Imanet as
described previously (Myers et al., 2012). Details of the injectate are
provided in Table 1. Speciﬁc radioactivities at the time of injection were
calculated in relation to the relative molecular weight of Ro15-4513
(326 mol/g).
2.3. PET data acquisition
PET scans were acquired on a Siemens/CTI ECAT EXACT HR
+(“962”) camera (Knoxville, TN, USA; (Spinks et al., 2000)) in 3D
mode. Ten-minute transmission scans for attenuation and scatter
correction were obtained prior to the dynamic emission scans using a
rotating 68Ge rod source. Each dynamic acquisition was 90.5 min long
and consisted of 24 frames of increasing length (1×30 s (s), 4×15 s,
4×60 s, 2×150 s, 10×300 s, 3×600 s). [11C]Ro15-4513 was injected as
an intravenous bolus injection of ~440 MegaBequerels (MBq; median
441 MBq, range 430–452 MBq; Table 1) at 30 s after the dynamic scan
start. Participants were scanned on two separate days with a median
interval of 12 days (range 7 – 59 days; Table 1).
The head position was maintained throughout and monitored with
the camera’s positioning laser. To compensate for minor head move-
ments during the dynamic scans, we used a post hoc frame-by-frame
realignment method, as described later (“PET data quantiﬁcation”
section). Sixty-three transaxial images were acquired per frame. Data
were reconstructed using Fourier rebinning (FORE; (Defrise et al.,
1997)) and 2D ﬁltered backprojection (FBP: ramp ﬁlter, kernel 2.0
millimetres (mm) Full Width at Half Maximum (FWHM)). The voxel
size of reconstructed images was 2.092 mm×2.092 mm×2.42 mm and
the axial (on-axis) resolution 5.6 mm (Spinks et al., 2000).
2.4. Input function derivation
As in previous studies, continuous and intermittent blood samples
were collected to allow the subsequent generation of arterial parent
plasma input functions (ppIFs; (Hammers et al., 2008; Riaño Barros
et al., 2014)). During the ﬁrst 15 min, blood was withdrawn continu-
ously at a rate of 300 millilitres (ml) per hour and radioactivity detected
in a bismuth germanium oxide detection system (Ranicar et al., 1991).
Intermittent discrete (10 ml) samples were taken using heparinised
syringes before the scan (baseline) and at the following time points
after the scan start: 4, 6, 8, 10, 20, 35, 50, 65, 80 and 90 min. These
discrete samples were used to quantify plasma and whole blood
radioactivity via centrifugation, as well as to allow quantiﬁcation of
the parent fraction of the radiotracer via high-performance liquid
chromatography. The plasma-over-blood ratio model and the metabo-
lite model were ﬁt for each scan, so that the whole blood measurements
between 0 and 15 min could be corrected for plasma-over-blood ratio
and parent fraction, respectively. The plasma-over-blood ratio model
used was as follows:
x x t
x t
1 − + ·
( / ) +1
s
s x
1 2
3 4 (1)
[where ts is the time from scan start in hours and x1 to x4 are the model
parameters]. The same sigmoidal model function was used to describe
the fraction of parent [11C]Ro15-4513 remaining in plasma, as in
(Myers et al., 2016).
Continuous ppIFs were derived using Clickﬁt in-house software
running in MATLAB R2014a (The MathWorks, Natick, MA, USA), as
described in detail in previous studies (Hammers et al., 2007b; Hinz
et al., 2007):
1) Cross-calibration of continuous and discrete whole blood radio-
activity concentration measurements (4, 6, 8, 10 min).
2) Multiplication of the cross-calibrated whole blood measurements
(0–15 min) by the sigmoid function obtained from ﬁtting the model
Table 1
Demographic and injectate details for the participants.
Participant no. Age Gender BMI Interval
(days)
Dose
(MBq)
Radiochemical purity
(%)
Co-injected
mass (μg)
Speciﬁc Radioactivity
(MBq/nmol)
1 40 M 25 12 431 99 2.0 72
435 98 2.4 59
2 38 M 27 30 430 99 4.4 32
437 98 2.2 66
3 39 M 20 11 447 99 3.0 49
441 99 5.1 28
4 49 M 34 59 440 97 2.6 55
442 98 3.5 42
5 44 M 23 7 452 96 3.0 26
444 98 0.4 72
Median 40 25 12 441 98 2.8 52
Interquartile range
(25th–75th perc)
39–44 23–27 11–30 435–443 98–99 2.2–3.4 34–64
Min 38 20 7 430 96 0.4 26
Max 49 34 59 452 99 5.1 72
BMI=Body mass index; MBq=MegaBequerels; Min=Minimum; Max=Maximum; μg=Micrograms; nmol=Nanomoles; no=Number; perc=Percentiles.
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to the plasma-over blood ratio.
3) Combination of the resultant continuous plasma radioactivity
concentration curve (0–15 min) with the discrete plasma radio-
activity concentration measurements (20, 35, 50, 65, 80 and
90 min) using spline interpolation.
4) Correction for parent radiotracer fraction by multiplication of the
resultant continuous plasma radioactivity concentration curve (0–
90 min) by the sigmoid function obtained from ﬁtting the model to
the parent fraction.
2.5. MRI data acquisition, analysis and generation of regions-of-
interest (ROIs)
All participants had 3D T1-weighted MRI scans with approximately
millimetric isotropic voxel sizes on a Philips Intera 3 Tesla (3 T) MRI
scanner (Philips, Best, The Netherlands) at the Robert Steiner MRI
Unit, Hammersmith Hospital, for use during co-registration and
region-of-interest (ROI) delineation. There was no gross structural
abnormality on any of the T1-weighted images.
To isolate the grey matter in each brain, the T1-weighted images
were segmented into tissue classes using SPM8 software (Statistical
Parametric Mapping, Wellcome Trust Centre for Neuroimaging,
University College London, London, www.ﬁl.ion.ucl.ac.uk/spm)
running in MATLAB R2014a. This process yielded grey matter
probability maps for each participant, which were thresholded at 0.5
probability (an arbitrary value which was selected as a trade-oﬀ
between over-exclusion of grey matter and over-inclusion of white
matter).
To delineate the ROIs in each brain, the T1-weighted images were
also anatomically segmented using MAPER (multi-atlas propagation
with enhanced registration (Heckemann et al., 2010)). Using high-
dimensional image registration, 30 MRI data sets, each associated with
manually determined labels of 83 regions (Hammers et al., 2003;
Gousias et al., 2008), were propagated to the target brain. Label fusion
was used to obtain an image which consisted of 83 labelled ROIs in
target space (Heckemann et al., 2006).
Each participant’s T1-weighted image and corresponding MAPER-
derived individual anatomical segmentations, as well as individual grey
matter probability images, were co-registered with the corresponding
processed PET summation image for test and retest scans separately,
using SPM8. For the cortical ROIs, the individual atlases in PET space
were then multiplied with the thresholded grey matter probability
maps using Analyze 8.1 imaging software (Mayo Clinic 2002). The
output grey-matter-masked, labelled ROI images were then used to
sample the dynamic or parametric PET images.
2.6. ROIs
We evaluated test – retest reliability of the quantiﬁcation methods
(12 variants) in six bilateral ROIs in total. Based on the expected
concentrations of GABAA receptors containing α5 subunits, we selected
ROIs to cover a range of binding: high-concentration limbic regions –
anterior cingulate gyrus and hippocampus; intermediate concentration
regions – fusiform (occipitotemporal) gyrus, inferior frontal gyrus and
insula; and a low concentration region – the occipital lobes. The
(entire) brainstem and alternatively the grey matter of the cerebellum
were used as pseudo-reference regions for the SRTMs. Here, the term
“pseudo-reference” region is used as neither the brainstem nor the
cerebellum are entirely devoid of α5 subunit speciﬁc binding. The
methods not relying on a reference region as input were also applied to
these regions, but comparison between variants was limited to the six
non-reference ROIs only. Regional time-activity curves (TACs) were
created by calculation of the mean radioactivity concentration over all
grey-matter masked voxels of both left and right hemisphere homo-
logues (excluding the brainstem which is not paired and was not grey-
matter masked), for each frame. Likewise, where parametric images
were used, the mean was calculated over all voxels of both homologues
(again excluding the brainstem).
2.7. PET data quantiﬁcation
Where required (one of 10 datasets, based on a maximum transla-
tion > 5 mm as estimated using SPM “Realign” function), the dynamic
PET images were de-noised and corrected for movement frame-by-
frame using wavelets in Piwave 8.0 (Studholme et al., 1997;
Turkheimer et al., 1999) running in MATLAB R2014a. The frame
starting at 150 s (frame 6) was used as reference due to its high signal-
to-noise ratio and the likelihood that the participant had remained still
during the ﬁrst three minutes of the scan. The frames 1–5 were not
corrected due to their low signal to noise ratio. The remaining frames
(6–24) were automatically resliced and re-concatenated with frames 1–
5 into a new dynamic image (Hammers et al., 2007b).
Summation images (also known as ‘add’ or ‘static’ images) were
created for frames 1–24, frames 16–21, and frames 22–24 with
correction for 11C radiodecay using MICKPM (Modelling, Input func-
tions, and Compartmental Kinetics – Parametric Maps) version 5.4
software (available on request from Rainer Hinz, Wolfson Molecular
Imaging Centre, University of Manchester, Manchester, UK), which
itself uses MATLAB R2009bSP1. The summation images were required
for calculation of global radioactivity concentrations, for use as the
reference image during co-registration of the T1-weighted MRI data,
and as the input for calculation of SUV images. A binary mask of the
brain, which encompassed approximately 9 mm beyond the outer
cortical boundary, was also created semi-automatically using Analyze
8.1 (Mayo Clinic, Rochester, New York) for use during the subsequent
generation of parametric images.
Quantiﬁcation of binding was performed as described below, using
the same ROIs for each variant. We used a 64-bit PC (Intel Core i5
5300U CPU 2.30 GHz, 8.0 GB RAM) with Windows 7 Enterprise
operating system. Variants in which parameters were calculated
directly from the ROI TAC data (generated as described in Section
2.6) are henceforth referred to as “regional”. Variants in which
parameters were calculated on a voxel-by-voxel basis in order to
generate parametric images are referred to as “voxelwise”; in this case
the parametric image itself was sampled (mean, standard deviation)
within same ROIs as used for regional variants. The quantiﬁcation
methods were:
1. Compartmental models, requiring arterial ppIFs
(a) Reversible two-compartment (one tissue compartment) model
with two rate constants and variable blood volume (2kbv)
(b) Reversible three-compartment (two tissue compartment) model
with four rate constants and variable blood volume (4kbv)
2. Graphical analyses, requiring arterial ppIFs
(a) Regional Logan’s graphical analysis with arterial ppIF
(b) Voxelwise Logan’s graphical analysis with arterial ppIF
3. Model-free analyses, requiring arterial ppIFs
(a) Regional “classic” (non-regularised) SA
(b) Voxelwise “classic” SA
4. Methods not requiring arterial ppIFs
(a) Voxelwise standardised uptake values (SUVs)
(i) 30.5–60.5 min
(ii) 60.5–90.5 min
(b) Regional SRTM using brainstem
(c) Voxelwise SRTM2 using brainstem
(d) Regional SRTM using cerebellum
(e) Voxelwise SRTM2 using cerebellum
2.8. Weighting of ROI and voxel TACs
For each participant, all ROI/voxel TACs (not yet corrected for
decay-correction) were weighted by the same values which were
C.J. McGinnity et al. NeuroImage 152 (2017) 270–282
273
calculated according to:
w L
T
= for frame (i = 1, 2, 3, …24; non − decay corrected data)i i
i (2)
[where Wi – weight for frame i; Li – length of frame i (seconds); Ti –
total of true coincidences (per second) for frame i].
For ROI TACs, the weights were normalised to sum(weights)=24
(i.e. number of frames), thresholded to max(weight)≤2.5, and then re-
normalised to sum(weights)=24. For voxel TACs, the weights were not
normalised but were thresholded to max(weight)/min(weight)≤1000,
according to the RPM (Receptor Parametric Mapping software) scheme
(Gunn et al., 1998; Aston et al., 2001).
2.9. Reversible compartmental models, requiring arterial ppIFs
MICK (Modelling, Input functions and Compartmental Kinetics)
version 5.2 software (available on request from Rainer Hinz, Wolfson
Molecular Imaging Centre, University of Manchester, Manchester, UK;
see Supplementary material) was used to ﬁt all regional compartmental
models with the Nelder-Mead optimisation algorithm (Nelder and
Mead, 1965). MICK uses MATLAB R2009bSP1.
2.9.1. 2kbv
In this model, three microparameters are derived: K1, rate constant
for inﬂux of the ligand from the plasma to the tissue compartment
containing free, non-speciﬁcally bound, and speciﬁcally bound ligand;
k2, eﬄux rate constant from the tissue back to plasma; and bv, the
blood volume term. The VT is then calculated according to the
compartmental model equation (Innis et al., 2007).
V K
k
=T 1
2 (3)
We used starting estimates of K1=0.01 ml cm-3 min-1,
k2=0.001 min-1 and bv=0.05.
2.9.2. 4kbv
In addition to K1 and k2 (described above for the 2kbv model), two
further rate constants were estimated: k3, which describes the transfer
from the free and non-speciﬁcally bound compartment to the speciﬁ-
cally bound (second tissue) compartment; and k4, which describes the
opposite transfer. Again, the blood volume term was also computed.
According to the consensus nomenclature (Innis et al., 2007):
⎛
⎝⎜
⎞
⎠⎟V
K
k
k
k
= 1+T 1
2
3
4 (4)
We used starting estimates of K1=0.01 ml cm-3 min-1, k2–
k4=0.001 min-1 and bv=0.05.
2.10. Graphical analyses, requiring arterial ppIFs
2.10.1. Regional Logan’s graphical analysis with arterial ppIF
Logan’s graphical analysis (Logan et al., 1990) is a linear analysis
applicable to radioligands with reversible binding. After some time (t*),
a plot of
∫ ∫TAC t dt
TAC t
ppIF t dt
TAC t
( ′) ′
( )
versus
( ′) ′
( )
t t
0 0
(5)
is linear; where ppIF(t) – metabolite-corrected plasma radioactivity
concentration at time t, TAC(t) – region of interest radioactivity
concentration at time t. For the two-tissue compartment model 4kbv,
the slope of the plot is:
⎛
⎝⎜
⎞
⎠⎟
K
k
k
k
bv1+ +1
2
3
4 (6)
[where bv is the blood volume term], from which VT can be calculated
as above. MICK was used to ﬁt regional Logan’s graphical analyses with
the Nelder-Mead optimisation algorithm (Nelder and Mead, 1965). We
used ﬁxed parameters of t*=1680 s (i.e. 28 min, based on a preliminary
inspection of the plots), bv=0.028 (the median across 83 brain regions
and the 10 scans, as estimated using 4kbv; interquartile range 0.022–
0.036), and equal weights (i.e. each frame was weighted by the same
value). The contribution due to vasculature (bv) was subtracted from
the ROI TAC prior to the graphical analysis.
2.10.2. Voxelwise Logan’s graphical analysis with arterial ppIF
Parametric images of [11C]Ro15-4513 VT were generated from
smoothed (isotropic ﬁlter with 2.0 mm FWHM) dynamic images and
the ppIFs using voxelwise Logan’s graphical analysis with ppIF, as
implemented in MICKPM, using the same ﬁxed parameters as listed
above.
2.11. Model-free analyses, requiring arterial ppIFs
2.11.1. Regional (non-regularised) SA
VTs for each ROI were obtained from the dynamic images and the
ppIFs using SA (Cunningham et al., 1993; Cunningham and Jones,
1993; Turkheimer et al., 1994), as implemented in MICK using the
non-negative least squares (NNLS) algorithm (Lawson and Hanson,
1995). The analysis used a base with 100 logarithmically-spaced
functions. The fast frequency boundary was kept at the default value
of 0.1 s-1. The theoretical slow frequency boundary is based on the
decay constant of 11C (t½≈20 min, decay constant 0005663 s
-1,
log10=−3.25). Based on previous work with tracers with relatively slow
kinetics (Hammers et al., 2007b; Riaño Barros et al., 2014) and
preliminary investigations (Barros et al., 2010b), we changed this to
0.00063 s-1 (log10=−3.20) in order to reduce noise.
2.11.2. Voxelwise SA
Parametric images of [11C]Ro15-4513 VT were generated from the
dynamic images and the ppIFs using voxelwise SA as implemented in
MICKPM using the NNLS algorithm, with the same number of
logarithmic functions and the same fast and slow frequency boundaries
as listed above.
2.12. Methods not requiring arterial ppIFs
2.12.1. Voxelwise standardised uptake values (SUVs)
Standardised uptake value images (SUVs) were generated from the
decay-corrected summation (add) images in SPM8 for frames 16–21
and for frames 22–24, i.e. from 30.5 to 60.5 and from 60.5 to 90.5 min
respectively, according to Kenney et al. (1941):
SUV radioactivity weight
injected dose
= ×
(7)
2.12.2. Regional SRTM using brainstem or alternatively using
cerebellum
GABAA receptors are widespread in the brain, and a true reference
region devoid of α5-subunit speciﬁc binding does not exist. Attempts
have been made to obviate arterial cannulation by using the brain
region with the lowest receptor concentration as a pseudo-reference
region (Turkheimer et al., 2012). The brainstem and the cerebellum are
two of the structures with the lowest concentration of α5 subunits in
the human brain (Fritschy and Mohler, 1995; Pirker et al., 2000;
Sieghart and Sperk, 2002; Veronese et al., 2016). We therefore used the
brainstem and the cerebellum, separately, as a pseudo-reference region
in the SRTM (Lammertsma and Hume, 1996) as implemented in
MICK, with Nelder-Mead optimisation. We used starting estimates
RI=0.95, k2a=0.001 min
-1 and k2a′ (k2RefRegion; eﬄux rate constant
from the reference compartment back to plasma) =0.001 min-1. The
C.J. McGinnity et al. NeuroImage 152 (2017) 270–282
274
model reduces to the following equation (Wu and Carson, 2002), from
which the binding potential (BPND; (Innis et al., 2007)) can be
calculated:
C t R C t R k k C t e( ) = ( ) + [ ′ − ] ( )*r a a r k t1 1 2 2 − a2 (8)
[where *– convolution operator; Cr(t) – radioactivity concentration in
the reference region tissue; C(t) – total radioactivity concentration
timecourse in the tissue; k2a – the apparent k2, i.e. k2/(1+BP); R1 – the
relative delivery i.e. the ratio K1/K1′ where K1′ (ml ml
-1 min-1) is the
rate constant for the inﬂux of the ligand from the plasma to the
reference compartment; t – time (min)].
2.12.3. Voxelwise SRTM2 using brainstem or alternatively using
cerebellum
Parametric images of BPND were generated from the dynamic
images using a two-step procedure, SRTM2 (Wu and Carson, 2002)
with 100 basis functions (Gunn et al., 1997) in MICKPM. Consistent
with the SA, we used beta min=0.00063 s-1. We used beta
max=0.014 s-1 (similar to Gunn et al., 1997). For each participant,
k2RefRegion was set to the global median of k2RefRegion estimates
derived from a ﬁrst-pass SRTM, which itself used the same ﬁxed
parameters and a tight brain mask (Wu and Carson, 2002).
2.13. Global radioactivity concentration
Global radioactivity concentrations were calculated for each decay-
corrected, summed radioactivity image (frames 01–24) with an in-
house script adapted from SPM (Hammers et al., 2007a), where the
global radioactivity concentration is deﬁned as the mean voxel value
within a mask. The mask itself is deﬁned as all voxels exceeding one-
eighth of the mean value of all voxels in the entire image matrix.
2.14. Outcome measures and statistical analyses
2.14.1. Comparison of test and retest injectate data
For the statistical testing we used SPSS for Windows version 22
software (IBM 2013, NY, USA). Injectate data (injected radioactivity,
radiochemical purity, co-injected mass of stable ligand, and speciﬁc
radioactivity at the time of injection) and global radioactivity concen-
tration were compared between test and retest sessions using Student’s
paired samples t-test (for data with a normal distribution) or the non-
parametric Wilcoxon signed-rank test (for data which diﬀered signiﬁ-
cantly from the normal distribution, i.e. Kolmogorov–Smirnov test p <
0.05).
2.14.2. Model ﬁt and within-ROI variability
The median residual sum of squares (RSS) was calculated for each
ROI, where available (regional variants), as a summary measure of the
ﬁt of the model to the observed data. Alternatively, the median within-
subject coeﬃcient of variation (WS-CV) was calculated, where available
(voxelwise variants), as a summary measure of the within-ROI
variability in the binding parameter.
2.14.3. Reproducibility
To assess test – retest variation (i.e. reproducibility), the median
(signed and alternatively absolute) percentage diﬀerence between test
and retest studies as well as their range was calculated for each ROI, for
each variant. The (signed) percentage test-retest diﬀerences of binding
parameters obtained was calculated according to:
Test retest difference test value retest value
test value retest value
− = 200 * ( − )
( + ) (9)
Median absolute percentage test – retest diﬀerences (MA-TD) of
< 10% were described as “low”; 10%≤MA-TD<15% were described
as “moderate”; 15%≤MA-TD<20% were described as “high”; and
MA-TD≥20% were described as “very high”.
2.14.4. Reliability
Reliability was calculated using the intraclass correlation coeﬃcient
(ICC; (MacLennan, 1993)):
ICC MSBS MSWS
MSBS dfWS MSWS
= −
+ ( × ) (10)
[where MS – mean sum of squares; BS – between-subject; WS –
within-subject; and df – degrees of freedom]. The ICC is provided to
allow assessment of the reliability of the measure as a function of both
within-subject variability and between-subject variability; the closer
the ICC to 1, the more reliable the variant, i.e. the smaller the within-
subject variability of the parameter compared with natural between-
subject variability. ICCs were computed in SPSS using the “one-way
random” model. We report the “single measures” ICC.
2.14.5. Regional heterogeneity
Finally, the ratio of binding in the highest-binding region (hippo-
campus) to the lowest-binding non-reference region (occipital lobes)
was calculated to allow assessment of each variant’s ability to depict the
known heterogeneity in α5 subunit availability across the brain. Ratios
(“x”) of 1.5≤x < 1.8 were described as “moderate” heterogeneity; 1.8≤x
< 2.0 were described as “high” heterogeneity; x≥2.0 were described as
“very high” heterogeneity.
Fig. 1. Example of Logan’s graphical analysis plot for a representative participant (2, test scan, for the hippocampus). ppIF(t) – metabolite-corrected plasma radioactivity concentration
at time t, TAC(t) – region of interest radioactivity concentration at time t.
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3. Results
3.1. Injectate
Details are given in Table 1. There were no signiﬁcant diﬀerences
between test and retest studies in terms of the amount of injected
radioactivity (median (range): test 440 (430–452) MBq, retest 441
(435–444) MBq, Student’s paired samples t-test p=0.90); the radio-
chemical purity (test 99 (96–99)%, retest 98 (98–99)%, Wilcoxon
signed-ranks test p=0.71); the co-injected mass of stable ligand (test
3.0 (2.0–4.4) μg, retest 2.4 (0.4–5.1) μg, Student’s paired samples t-
test p=0.78); or the speciﬁc radioactivity at the time of injection (test
49 (26–72) MBq/ηmol, retest 59 (28–72) MBq/ηmol, Student’s paired
samples t-test p=0.66).
3.2. Global radioactivity concentration
There was no signiﬁcant diﬀerence in global radioactivity concen-
tration between test and retest studies: test 4.65 (range 3.50–5.39)
kiloBequerels per millilitre (kBq/ml), retest 4.22 (3.54–4.75) kBq/ml,
Student’s paired samples t-test p=0.14.
3.3. Reproducibility and reliability of blood and PET data
quantiﬁcation
See Sections 2 and 3 of the Supplementary material for details of
the parameters derived from the metabolite and plasma-over-blood
ratio models, and the six PET quantiﬁcation methods (12 variants).
Figs. 1 to 5 provide examples of the output.
3.4. Comparison between analysis variants
The analyses did not produce any outliers for the ROIs (where
“outlier” is deﬁned as VT or BPND≤0 and/or WS-CV>50% for regional
variants and mean VT or mean BPND≤0 and/or WS-CV>100% for
voxelwise variants). For well-performing regional variants, there was
no evidence of bias or structure in the weighted residuals.
Table 2 provides an overview of the MA-TDs (%) for the six
diﬀerent methods (12 variants). The MA-TDs were very low to low
for all SRTM variants and voxelwise SA (≤5%); MA-TDs were also low
( < 10%) for most ROIs with the 4kbv model. These variants all had
very low test-retest diﬀerences in the hippocampus (< 5%).
Table 3 provides an overview of the BS-CV (%) for the six diﬀerent
methods (12 variants). The median BS-CVs were moderate for most or
all of the ROIs (11–15%) for several variants: 2kbv, 4kbv, voxelwise
Logan’s graphical analysis, both regional and voxelwise SA, and SUVs
(30.5–60.5 and 60.5–90.5 min). The remaining variants, particularly
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Fig. 2. Example of compartmental model ﬁts for a representative participant (1, retest scan) for the hippocampi (A, circles) and the occipital lobes (B, squares). The 2kbv model is
depicted by blue dashed lines, and the 4kbv model is depicted by red dashed lines. The 4kbv model ﬁts better than the 2kbv model in the α5-subunit-rich hippocampus. 2kbv – reversible
one tissue compartment model with variable blood volume; 4kbv – reversible two tissue compartment model with variable blood volume; kBq/ml – kiloBequerels per millilitre. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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SRTMs using a pseudo-reference region, were characterised by low
(≤10%) BS-CVs for nearly all ROIs.
Table 4 provides an overview of the ICCs for the six diﬀerent
methods (12 variants). The median ICC was excellent (>0.80) for both
the voxelwise SA, and for the voxelwise SRTM2 with the cerebellum as
a pseudo-reference region. Regional SRTM using cerebellum also
yielded a good (>0.70) median ICC. Other variants yielded low to
moderate (≤0.70) median ICCs. Regarding the hippocampus, the 4kbv
model, voxelwise SA, and both regional and voxelwise SRTM/SRTM2
using cerebellum, and voxelwise SRTM2 using the brainstem all
yielded excellent (>0.85) median ICCs. Regional SRTM with the
brainstem yielded a very good median (0.77) ICC.
Table 4 also shows the ratio between the hippocampus, which for all
variants was the region with highest binding, and a low-binding non-
reference region (occipital lobes). Voxelwise SA, regional SRTM using
brainstem, and both regional SRTM and voxelwise SRTM2 using the
cerebellum all yielded very high ratios (≥2.0).
4. Discussion
We describe the test – retest reproducibility and reliability of
quantiﬁcation of the availability of the GABAA receptor α5 subunit in
ﬁve healthy human participants. Our major ﬁnding is that very good to
excellent reproducibility of estimates, in terms of percentage test –
retest diﬀerence, is achievable using regional and voxelwise implemen-
tations of the SRTM and also using model-free, voxelwise SA.
Voxelwise SA was the best-performing variant, in terms of ICCs,
and one of the best in terms of percentage test – retest diﬀerence. This
variant also yielded a slightly higher median BS-CV (11%) than SRTM-
based variants, and had a high ratio of hippocampal-to-occipital lobe
VT. We note that voxelwise SA markedly outperformed SA applied to
regional TACs. This phenomenon has also been documented for the
opioid receptor radioligand [11C]diprenorphine (Hammers et al.,
2007b) and the cannabinoid receptor type 1 radioligand, [11C]
MePPEP (Riaño Barros et al., 2014). We suggest that the voxelwise
approach beneﬁts from the ﬂexibility to be able to accommodate
diﬀerences in blood volume, tissue class partial volume and receptor
concentration between voxels, in contrast to variants that use the
averaged regional TAC.
The assumptions inherent to SA are that: 1) the compartmental
systems are strongly connected; 2) the exchange of material with the
environment is conﬁned to a single compartment; and 3) there is no
possibility for material to pass from one compartment through two or
more compartments back to the initial compartment (Schmidt, 1999).
There is no evidence to indicate that SA is biased towards or against
any particular patient population. An arterial input function is re-
quired, as the ﬁt assumes a sum of positive series of convolution
integrals of the input function. One advantage of SA is that it is “data
driven”, i.e. a priori model selection is not required. Like all voxel-
based methods, the generation of parametric VT images via voxelwise
SA has the added advantage of allowing whole-brain surveys in
diseases where the exact localisation of pathology is not known, e.g.
refractory focal epilepsy.
Of the compartmental models, the 2kbv model had a very high
median percentage test – retest variability (MA-TD; 25%); whilst the
4kbv model had an acceptable MA-TD (8%). However, a wide range of
percentage test – retest variability was observed across participants for
A – Logan’s (graphical) analysis
-1                 VT                                   18
B – (Exponential) SA
Fig. 3. VT images for participant 2 (test scan), co-registered to the corresponding T1-
weighted MRI image. The images were produced by voxelwise Logan’s graphical analysis
with ppIF (A – top row), and voxelwise (exponential) SA (B, bottom row). The dynamic
data were smoothed (isotropic ﬁlter with 2.0 mm FWHM) prior to Logan’s graphical
analysis. Note the high binding in temporal regions, and the low binding in the
cerebellum. Images are shown in radiological orientation (left on right). The colour bar
depicts VT. SA – spectral analysis, VT – volume-of-distribution. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this
article).
A – Logan’s (graphical) analysis
C – SRTM(2) brainstem
B – (Exponential) SA
-2                                 BPND                                16
Fig. 4. BPND images for participant 2 (test scan), co-registered to the corresponding T1-
weighted MRI image. For comparison, BPND images were produced for voxelwise Logan’s
graphical analysis with ppIF (A – top row) and voxelwise (exponential) SA (B, second
row) by dividing the VT image by the mean of the brainstem (pseudo-reference region) VT
and then subtracting 1. BPND images are shown for SRTM2 using the brainstem (C –
third row) as a pseudo-reference region. The dynamic data were smoothed (isotropic
ﬁlter with 2.0 mm FWHM) prior to Logan’s graphical analysis. Note the high binding in
temporal regions, and the low binding in the cerebellum. Images are shown in
radiological orientation (left on right). The colour bar depicts BPND. BPND – binding
potential relative to non-displaceable binding, ppIF – (arterial) parent plasma input
function; SA – spectral analysis, VT – volume-of-distribution. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this
article).
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each region, other than in the hippocampus (3%, range −2–7%). These
data are in keeping with previous ﬁndings, in which the ﬁts with two-
tissue compartment models were better than those seen with one-tissue
compartment models (Asai et al., 2009; Myers et al., 2012; Myers et al.,
2012, 2016).
While [11C]Ro15-4513 has highest aﬃnity for GABAA receptors
containing α5 subunits (Lingford-Hughes et al., 2002), it also binds to
GABAA receptors containing α1 and other α subunits, albeit with
approximately 10–15 times lower aﬃnity (Hadingham et al., 1993;
Luddens et al., 1994; Myers et al., 2012; Stokes et al., 2013). Recently,
human heterologous competition data acquired from healthy males
using the α5-subunit-selective negative allosteric modulator,
Basmisanil (RG1662), suggested that α5-speciﬁc binding accounts for
60–70% of the speciﬁc binding in most regions (Myers et al., 2016). As
the regional distribution of α subunits overlaps, the tissue kinetics,
model ﬁts and hence reliability will vary according to the proportion of
subunits (Maeda et al., 2003; Myers et al., 2012). Model-free quanti-
ﬁcation, such as with SA, oﬀers ﬂexibility to deal with the complex
compartmentalisation of the radioligand targets (Myers et al., 2012;
Riaño Barros et al., 2014).
Logan’s graphical analyses had a very high MA-TD, whether applied
to regional TACs or on a voxel-by-voxel basis. It is possible that more
than nine frames are required to accurately ﬁt the plot, although we did
smooth the dynamic images before voxelwise analyses. Also, the
analyses assumed a ﬁxed blood volume contribution of 0.028, the
median derived from multiple regions and scans, which cannot be
correct for each ROI in each participant.
In the present study, we quantiﬁed the total VT, rather than
attempting to isolate the presumed α5-subunit-speciﬁc volume-of-
distribution (Vs), for example via bandpass SA (Stokes et al., 2014).
However, accurate isolation of the Vs is challenging and is vulnerable to
the eﬀects of tissue heterogeneity and noise. Whilst Vs appears to
exhibit a tight relationship with the ‘true’ α5-subunit-speciﬁc VT in
regions with moderate or high α5 subunit concentration, the total VT
also exhibits a tight, linear association (Myers et al., 2016).
As expected, our analyses revealed that the reproducibility of [11C]
Ro15-4513 VT was sensitive to multiple methodological choices, e.g.
derivation of the input function and method used to calculate the
weighting factors (e.g. Yaqub et al., 2006; data not shown).
Non-invasive PET studies are preferable in both research and
clinical studies, in order to avoid the discomfort and slight risks
attributable to arterial cannulation, a procedure which demands
expertise. GABAA receptor α5 subunits are expressed throughout the
brain, and a true reference region does not exist. Here we used the
brainstem and alternatively the cerebellum as pseudo-reference re-
gions, based on their near-negligible expression of the α5 subunit
(Fritschy and Mohler, 1995; Pirker et al., 2000; Sieghart and Sperk,
2002; Veronese et al., 2016). This approach is supported by recent data
that suggest the Vs is low in the cerebellum and extremely low in the
pons (Myers et al., 2016). In the present study, both variants yielded
reproducible data, in terms of percentage test – retest diﬀerence,
whether applied to regional TACs or on a voxel-by voxel basis. BS-CV
was low, however, which perhaps reﬂects a bias of the reference region
methods. The actual BPND values were much lower for the SRTMs
when using cerebellum as the pseudo-reference rather than the
brainstem, which probably reﬂects greater α5-subunit-speciﬁc binding
in the former (Myers et al., 2016). A wider range of percentage test –
retest diﬀerence was seen for the brainstem than for the cerebellum
with compartmental models. We observed lower signal-to-noise ratio,
i.e. noisier time-activity curves, for the smaller brainstem ROI, which
impaired model ﬁtting.
Whilst the recent Basmisanil (RG1662) blocking study found a
tight, linear relationship between BPND and the ‘true’ α5-subunit-
speciﬁc volume-of-distribution with both variants (Myers et al., 2016),
SRTMs should only be used if even very small intra- or between-subject
variations in the amount of GABAA receptor-speciﬁc binding in these
pseudo-reference regions can be excluded. It might be possible to
improve on these results by utilising a sub-region of the brainstem or
cerebellum, or via a more sophisticated pseudo-reference region
approach (e.g. Turkheimer et al., 2012).
SUVs can constitute a simple and reliable measure of radioligand
binding that obviates the need for arterial blood sampling (Riaño
Barros et al., 2014). In the present study, [11C]Ro15-4513 SUVs were
moderately reproducible overall (median MA-TD 11%), but had a wide
range in percentage test – retest diﬀerence for most regions. The SUVs
were moderately reliable (median ICC 0.70), which is partly attribu-
table to the large BS-CV (median 15%). Overall these data suggest that
factors other than weight and injected dose signiﬁcantly inﬂuence
reproducibility. Given the performance of voxelwise SA with arterial
input function, and the moderately-high MA-TD we observed in the
area under the metabolite model curve (12%, see Supplementary
material, Table 2), we hypothesise that such factors include the rate
of metabolism of the parent radioligand.
The present study is limited by the sample size; in particular ICCs
must be treated with caution when using paired data acquired from
eight or less participants (Walter et al., 1998; Shoukri et al., 2004). As
-2                                 BPND                                8
A – Logan’s (graphical) analysis
B – (Exponential) SA
C – SRTM(2) cerebellum
Fig. 5. BPND images for participant 2 (test scan), co-registered to the corresponding T1-
weighted MRI image. For comparison, BPND images were produced for voxelwise Logan’s
graphical analysis with ppIF (A – top row) and voxelwise (exponential) SA (B, second
row) by dividing the VT image by the mean of the cerebellum (pseudo-reference region)
VT and then subtracting 1. BPND images are shown for SRTM2 using the cerebellum (C,
bottom row) as a pseudo-reference region. The dynamic data were smoothed (isotropic
ﬁlter with 2.0 mm FWHM) prior to Logan’s graphical analysis. Note the high binding in
temporal regions, and the low binding in the cerebellum. Images are shown in
radiological orientation (left on right). The colour bar depicts BPND. BPND – binding
potential relative to non-displaceable binding, ppIF – (arterial) parent plasma input
function; SA – spectral analysis, VT – volume-of-distribution. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this
article.).
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the free fraction of parent radioligand in the plasma was not quantiﬁed,
we cannot comment on the reproducibility or reliability of BPf or VTf
(Innis et al., 2007). However, voxelwise SA based on arterial ppIFs that
were not corrected for plasma free fraction still yielded reproducible
and reliable VT data. The test – retest scan interval was short, but
varied from a week to two months between participants; this variable
was not associated with reproducibility.
The lack of females in our study population is an additional
limitation. To the best of our knowledge, the potential inﬂuence of
the menstrual cycle on the availability of the GABAA receptor or of the
α5 subunit in particular has not been studied. However, the menstrual
cycle inﬂuences GABA concentration in the frontal lobe, as measured
by proton magnetic resonance spectroscopy (e.g. Harada et al., 2011;
De Bondt et al., 2015), which could conceivably lower test – retest
reproducibility. Hence, conﬁrmation of our ﬁndings in women would
be desirable.
5. Conclusions
Quantiﬁcation of [11C]Ro15-4513 binding shows very good to
excellent reproducibility with SRTMs and voxelwise SA.
Quantiﬁcation of binding in the α5-subunit-rich hippocampus is
particularly reliable. Whilst SA necessitates arterial blood sampling,
it is preferable to the SRTMs due to the lack of a true reference region.
[11C]Ro15-4513 PET is well-placed as a tool to study the availability of
the GABAA receptor α5 subunit in health and neuropsychiatric disease.
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Table 2
MA-TDs (median absolute t-rt differences (%)) for participants’ parameter estimates (BPND/SUV/VT) obtained with the six diﬀerent methods (12 variants).
Method 2kbv 4kbv Logan’s
graphical
analysis
Logan’s
graphical
analysis
SA SA SUV
(30.5–
60.5 min)
SUV
(60.5–
90.5 min)
SRTM
brainstem
SRTM2
brainstem
SRTM
cerebellum
SRTM2
cerebellum
Parameter VT VT VT VT VT VT SUV SUV BPND BPND BPND BPND
Regional/
Voxelwise
Regional Regional Regional Voxelwise Regional Voxelwise Voxelwise Voxelwise Regional Voxelwise Regional Voxelwise
ACG 28 7 18 19 10 4 11 21 5 6 2 1
Fusiform
gyrus
28 14 19 20 14 10 10 15 8 6 5 4
Hippocampus 22 3 13 9 6 2 6 16 3 2 3 2
Inferior
frontal
gyrus
17 5 8 9 7 5 11 14 5 5 5 4
Insula 27 8 16 17 14 1 12 20 7 6 3 2
Occipital
lobes
21 8 17 15 15 8 13 17 4 1 5 3
Median 25 8 17 16 12 5 11 17 5 6 4 3
(iqr) (21–28) (6–8) (14–18) (11–19) (8–14) (3–7) (10–12) (15–19) (4–7) (3–6) (3–5) (2–4)
2/4kbv=2/4 rate constant compartmental models with variable blood volume, ACG=Anterior cingulate gyrus, BPND=Binding potential relative to non-displaceable binding,
iqr=Interquartile range, SUV=Standardised uptake value, ROI=Region-of-interest, SA=Spectral analysis, SRTM=Simpliﬁed reference tissue model, t-rt=test-retest, VT=Volume-of-
distribution.
Table 3
Mean between-subject coefficients of variation (BS-CV; %) for participants’ parameter estimates (BPND/SUV/VT) obtained with the six diﬀerent methods (12 variants).
Method 2kbv 4kbv Logan’s
graphical
analysis
Logan’s
graphical
analysis
SA SA SUV
(30.5–
60.5 min)
SUV
(60.5–
90.5 min)
SRTM
brainstem
SRTM2
brainstem
SRTM
cerebellum
SRTM2
cerebellum
Parameter VT VT VT VT VT VT SUV SUV BPND BPND BPND BPND
Regional/
Voxelwise
Regional Regional Regional Voxelwise Regional Voxelwise Voxelwise Voxelwise Regional Voxelwise Regional Voxelwise
ACG 15 9 12 12 10 10 16 20 5 5 8 8
Fusiform
gyrus
15 26 12 12 14 14 14 19 5 6 7 8
Hippocampus 15 9 10 11 12 11 13 18 8 9 8 11
Inferior
frontal
gyrus
12 20 10 10 15 12 18 22 8 8 9 10
Insula 14 11 10 10 10 10 14 18 6 6 7 8
Occipital
lobes
11 18 9 10 14 10 19 21 7 7 9 9
Median 15 15 10 11 13 11 15 20 7 7 8 9
(iqr) (13–15) (10–20) (10–12) (10–12) (11–14) (10–12) (14–18) (18–21) (5–8) (6–8) (7–9) (8–10)
2/4kbv=2/4 rate constant compartmental models with variable blood volume, ACG=Anterior cingulate gyrus, BPND=Binding potential relative to non-displaceable binding,
iqr=Interquartile range, SUV=Standardised uptake value, ROI=Region-of-interest, SA=Spectral analysis, SRTM=Simpliﬁed reference tissue model, t-rt=test-retest, VT=Volume-of-
distribution.
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